(Q33956796)

English

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

12

object named as

Stefan Zeuzem

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Maria Beumont-Mauviel

19

object named as

Maria Beumont-Mauviel

0 references

10

object named as

Fred Poordad

0 references

object named as

Igor Nikitin

9

0 references

object named as

Robert Flisiak

4

0 references

Patrick Marcellin

7

object named as

Patrick Marcellin

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

2

object named as

Maria Buti

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

3

object named as

Gregory J Dore

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Michael W Fried

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Peter Ferenci

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Ira Jacobson

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Michael Manns

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Morris Sherman

11

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jane Scott

13

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Leen Gilles

14

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Oliver Lenz

15

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Monika Peeters

16

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Vanitha Sekar

17

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Goedele De Smedt

18

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Maria Beumont-Mauviel

19

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

11 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1918-1929

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112500

28 July 2018

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112500

28 July 2018

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112500

28 July 2018

Host genomics and HCV treatment response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112500

28 July 2018

Response-guided telaprevir combination treatment for hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112500

28 July 2018

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112500

28 July 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112500

28 July 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112500

28 July 2018

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112500

28 July 2018

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112500

28 July 2018

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112500

28 July 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112500

28 July 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112500

28 July 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112500

28 July 2018

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26641

21 January 2018

In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26641

21 January 2018

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26641

21 January 2018

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26641

21 January 2018

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26641

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26641

21 January 2018

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26641

21 January 2018

Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/23907700

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A SPECIAL MEETING REVIEW EDITION: Updates in the Treatment of Hepatitis C Virus Infection From EASL 2012: The 47th Annual Meeting of the European Association for the Study of the LiverApril 18-22, 2012 • Barcelona, SpainSpecial Reporting on:• Safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/23907700

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/HEP.26641

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33956796&oldid=1991941264"